Active Specific Immunotherapy plus Doxorubicin Chemotherapy Mediates Durable Remission of Lethal Canine Hemangiosarcoma

• Published in: The Journal of immunology (1950) 2017-05, Vol.198 (1_Supplement), p.198-198.3
• Main Authors: Konduri, Vanaja, Halpert, Matthew M, Chen, Yunyu, Liang, Dan, Levitt, Jonathan M, Neal, Brittany, Husdon, Caleb, Hottinger, Heidi, Piscoya, Sindy, Wilson, Nicola, DiBernardi, Lisa, Stallings, Shonda, Omarbekov, Zarkhyn, Seelhoff, Lori, Ramirez, Oscar, Yao, Qizhi C, Bhardwaj, Ratan D, Ravi, Vinod, Douglass, Laurel, Decker, William K
• Format: Article
• Language: English
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.198.Supp.198.3

Angiosarcoma is a deadly neoplasm of the vascular endothelium. Metastases are often present at diagnosis, and 5-year survival is only 10–30%. While the disease is uncommon in humans, angiosarcoma is a major killer of companion dogs, responsible for 120,000 deaths per year in the US. The canine disease (HSA) presents as acute hemoabdomen secondary to splenic rupture. Even if life-saving splenectomy is performed, median OS is only 48 days, and one-year survival is 0%. Here we report an interim analysis of a phase I multi-site, open-label trial of chemo-immunotherapy performed on consecutively-presenting splenectomized canines with verified HSA. Subjects received doxorubicin plus an autologous cell-therapy that generates durable CD8+ memory. Disease was monitored monthly by abdominal ultrasound, chest x-ray, and echocardiogram. At the time of this submission, median OS had not yet been reached in the per protocol population, with 75% of animals alive and healthy at up to one year post-splenectomy (p